Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

  1. Sangro, B.
  2. Galle, P.R.
  3. Kelley, R.K.
  4. Charoentum, C.
  5. De Toni, E.N.
  6. Ostapenko, Y.
  7. Heo, J.
  8. Cheng, A.-L.
  9. Wilson Woods, A.
  10. Gupta, C.
  11. Abraham, J.
  12. McCoy, C.L.
  13. Patel, N.
  14. Negro, A.
  15. Vogel, A.
  16. Abou-Alfa, G.K.
Revue:
Journal of Clinical Oncology

ISSN: 1527-7755,  0732-183X

Année de publication: 2024

Volumen: 42

Número: 23

Pages: 2790-2799

Type: Article

DOI: 10.1200/JCO.23.01462 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus